Your browser doesn't support javascript.
loading
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.
Cameron, David; Morden, James P; Canney, Peter; Velikova, Galina; Coleman, Robert; Bartlett, John; Agrawal, Rajiv; Banerji, Jane; Bertelli, Gianfilippo; Bloomfield, David; Brunt, A Murray; Earl, Helena; Ellis, Paul; Gaunt, Claire; Gillman, Alexa; Hearfield, Nicholas; Laing, Robert; Murray, Nicholas; Couper, Niki; Stein, Robert C; Verrill, Mark; Wardley, Andrew; Barrett-Lee, Peter; Bliss, Judith M.
  • Cameron D; Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK. Electronic address: D.Cameron@ed.ac.uk.
  • Morden JP; ICR-CTSU, Division of Clinical Studies, Institute of Cancer Research, London, UK.
  • Canney P; Department of Oncology, Beatson Hospital, Glasgow, UK.
  • Velikova G; St James' Institute of Oncology, University of Leeds, Leeds, UK.
  • Coleman R; Department of Oncology, Weston Park Hospital, Sheffield, UK.
  • Bartlett J; Department of Diagnostic Development, Ontario Institute for Cancer Research, Toronto, ON, Canada.
  • Agrawal R; Department of Oncology, Shrewsbury & Telford Hospitals NHS Trust, Shrewsbury, UK.
  • Banerji J; ICR-CTSU, Division of Clinical Studies, Institute of Cancer Research, London, UK.
  • Bertelli G; Department of Oncology, Singleton Hospital, Swansea, UK.
  • Bloomfield D; Department of Oncology, Royal Sussex County Hospital, Brighton, UK.
  • Brunt AM; Department of Oncology, Royal Stoke University Hospital, Stoke-on-Trent, UK.
  • Earl H; Department of Oncology, Addenbrooke's Hospital, Cambridge, UK.
  • Ellis P; Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Gaunt C; Cancer Research UK Clinical Trials Unit, University of Birmingham, UK.
  • Gillman A; ICR-CTSU, Division of Clinical Studies, Institute of Cancer Research, London, UK.
  • Hearfield N; Clinical Trials Research Unit (CTRU), University of Leeds, Leeds, UK.
  • Laing R; Department of Oncology, Royal Surrey County Hospital, Guildford, UK.
  • Murray N; Department of Oncology, Southampton General Hospital, Southampton, UK.
  • Couper N; Cancer Clinical Trials Unit Scotland (CaCTUS), Glasgow, UK.
  • Stein RC; Department of Oncology, NIHR University College London Hospitals Biomedical Research Centre, London, UK.
  • Verrill M; Department of Oncology, Northern Centre for Cancer Care, Freeman Hospital, Newcastle, UK.
  • Wardley A; Department of Oncology, Christie Hospital, Manchester, UK.
  • Barrett-Lee P; Department of Oncology, Velindre NHS Trust, Cardiff, UK.
  • Bliss JM; ICR-CTSU, Division of Clinical Studies, Institute of Cancer Research, London, UK.
Lancet Oncol ; 18(7): 929-945, 2017 07.
Article en En | MEDLINE | ID: mdl-28600210
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Carcinoma / Epirrubicina / Protocolos de Quimioterapia Combinada Antineoplásica / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Carcinoma / Epirrubicina / Protocolos de Quimioterapia Combinada Antineoplásica / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Año: 2017 Tipo del documento: Article